Acelyrin, Inc. (SLRN)
NASDAQ: SLRN · Real-Time Price · USD
2.600
+0.430 (19.82%)
Feb 21, 2025, 4:00 PM EST - Market closed
Acelyrin Employees
Acelyrin had 135 employees as of December 31, 2023. The number of employees increased by 88 or 187.23% compared to the previous year.
Employees
135
Change (1Y)
88
Growth (1Y)
187.23%
Revenue / Employee
n/a
Profits / Employee
-$1,958,556
Market Cap
260.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 135 | 88 | 187.23% |
| Dec 31, 2022 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
SLRN News
- 1 day ago - ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - GlobeNewsWire
- 12 days ago - ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN - Business Wire
- 14 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. - PRNewsWire
- 6 weeks ago - Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 weeks ago - ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - GlobeNewsWire
- 7 weeks ago - ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - GlobeNewsWire
- 2 months ago - ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - GlobeNewsWire
- 3 months ago - Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript - Seeking Alpha